Referencing the clinically validated strategy of combining BRAF and MEK inhibitors in treating melanoma [89], they investigated combinations of AMG510 and various inhibitors of the MAPK and AKT signaling pathways, including inhibitors of HER kinases, EGFR, SHP2, PI3K, AKT and MEK. Here, MAP2K7 is linked to melanoma.